Latest news with #chroniccare
Entrepreneur
05-08-2025
- Business
- Entrepreneur
Linda Yaccarino Is a CEO Again After X Departure
The former NBC executive and X leader is now the CEO of an online GLP-1 health management company. Linda Yaccarino, the former X CEO who resigned in June, has moved on to another chief executive role. Digital health platform, eMed Population Health, which offers chronic care management related to obesity and type 2 diabetes (and access to GLP-1s), announced in a press release on Tuesday that it has appointed Yaccarino as CEO. Related: Who Is Linda Yaccarino? Everything to Know About X's Former CEO "The healthcare industry has been disrupted by technology, but not yet completely transformed by it," Yaccarino said in a statement. "There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before." In the statement, eMed says its mission is "to make safe, effective, and sustainable chronic care accessible directly through an all-in-one, digital-first experience." Yaccarino began as CEO of X in May of 2023, about six months after Elon Musk bought the company, then known as Twitter, for $44 billion. Related: 'Futures Are Intertwined': Elon Musk xAI Buys His Own Social Media Platform, X, in a $33 Billion Deal When Yaccarino publicly announced her resignation on X in June, owner Musk replied to the post with a short: "Thank you for your contributions." Before joining X in 2023, Yaccarino was the chairman of global advertising and partnerships at NBCUniversal. Join top CEOs, founders and operators at the Level Up conference to unlock strategies for scaling your business, boosting revenue and building sustainable success.
Associated Press
09-07-2025
- Health
- Associated Press
Giroir Commends Formation of Congressional BIOTech Caucus
Former Senior Trump Health Official Urges Focus on Innovative 'Upstream' Approaches that Disrupt Current Paradigm of Costly Chronic Care ATLANTA, July 9, 2025 /PRNewswire/ -- Brett P. Giroir, M.D., former Assistant Secretary of Health and Acting FDA Commissioner in the first Trump Administration, praised the recently announced formation of the bipartisan BIOTech Caucus and noted the critical importance of its mission to engage with sector leaders and to build awareness and bioliteracy among Members of Congress. 'I applaud Reps. Chrissy Houlahan (D-PA) and Stephanie Bice (R-OK) for seizing the initiative to form the BIOTech Caucus. With new FDA reform initiatives and focused efforts in Congress, innovative biotech companies will be better able to shatter treatment paradigms that have become too comfortable and too profitable for Big Pharma to change,' said Giroir, CEO of Altesa BioSciences. 'This is precisely why I chose to lead a small innovative biotech company after completing my US government service,' he continued. 'The federal government can play a key role to help incentivize bio-entrepreneurship and leverage capital markets for the benefit of U.S. biotech companies poised to provide seismic, beneficial impacts to patients, taxpayers and the public-at-large.' Chronic Obstructive Pulmonary Disease (COPD) treatment as paradigm shift example: Giroir pointed to the transformation needed in the treatment of COPD, a condition that negatively impacts the health and well-being of 17 million Americans and nearly 500 million globally. COPD, the Altesa CEO noted, costs the U.S. approximately $50 billion annually in health care spending and is predicted to become the world's leading cause of death in 15 years. 'Until we can eliminate the underlying causes of COPD, namely smoking and air pollution, patients deserve better than costly downstream immune-modifying injections that only help a minority of COPD patients avoid a minority of flare-ups,' he continued. Instead, he said, patients must be empowered to better care for their disease by using and integrating wearable technologies, at-home diagnostics, artificial intelligence, and specific treatments for the number one cause of exacerbations - respiratory virus infections. 'Diagnostics coupled with effective oral medicines have transformed our treatment of flu, COVID, Hepatitis C, and HIV. If we can identify respiratory viruses early- and treat them early on, there is a good chance that we can markedly and cost-effectively reduce exacerbations of COPD, asthma, and other lung conditions,' the Altesa BioSciences CEO said. Giroir pointed to Altesa BioSciences collaborator, Sensifai Health, as emblematic of the needed emphasis on AI and wearables technology to facilitate upstream treatments to help people experiencing COPD. 'The entire rationale of 'upstream' disease treatment is to intervene before health crises occur,' Giroir pointed out. 'Sensifai's objectives align perfectly with our mission to deliver transformative respiratory therapeutics at a time when they can be most effective.' He noted a peer-reviewed study published in The Lancet Digital Health last week details the fact Sensifai's AI platform is the world's first wearable-powered system to predict acute inflammation with 90% sensitivity. To encourage paradigm change, Giroir urged payers like Medicare and Medicaid to evaluate innovative care models that compare costly chronic downstream therapies versus common-sense upstream approaches like AI-assisted wearables, vaccination, preemptive treatment of viral infections, exercise, digital coaching, and Vitamin D supplementation. 'If such commonsense approaches proved effective – and I believe they will – the lives of COPD patients would be forever changed, and the U.S. health care system would save tens of billions of dollars annually,' Giroir concluded. 'These are the types of conversations Congress needs to hear, and I look forward to working in a positive, constructive manner with the BIOTech Caucus to help detail and explain the 'upstream' diagnostic and treatment changes we can no longer afford to ignore.' Download study: About Altesa BioSciences, Inc. Altesa BioSciences is a clinical-stage pharmaceutical company dedicated to developing new treatments for age-old threats to human health: high-consequence viral infections. These infections are particularly severe in vulnerable people, including those with chronic health conditions, like lung diseases, as well as the elderly and many people in underserved communities. About Sensifai Health Inc. Sensifai Health is a Canadian-Israeli Preemptive Health startup at the forefront of bioconvergence. Its AI-powered platform continuously analyzes data from wearable biometric sensors to deliver early alerts of systemic inflammation before symptoms appear. By identifying silent immune signals in vulnerable individuals, Sensifai enables timely intervention that helps prevent critical health events, reduce hospitalizations, and improve long-term outcomes. Contact: Media Inquiries: Mia Heck Cellular (210) 284-0388 [email protected] View original content to download multimedia: SOURCE Altesa Biosciences Inc.
Yahoo
07-07-2025
- Business
- Yahoo
Medsien unveils care management programme
Medsien has introduced its Advanced Primary Care Management (APCM) programme, a solution aimed at assisting healthcare organisations in transitioning to the US Centers for Medicare & Medicaid Services' (CMS) new care model. This model aims to enhance chronic care delivery and promote sustainable growth. Medsien's APCM programme is a response to the CMS' 2025 initiative, which introduced a new direction for Medicare reimbursement. The traditional time-based needs have been replaced with a monthly per-patient payment model, using G0556, G0557, and G0558 billing codes. Healthcare providers can categorise patients according to their risk levels and receive consolidated payments for a wide array of services, encompassing chronic, primary and transitional care management, virtual visits, telehealth check-ins, and remote evaluations. The transition underscores the significance of preparedness and continuity of care, rather than administrative time tracking, enabling practices to concentrate on patient care. The APCM programme by Medsien presents a swift, scalable, and forward-thinking approach that allows medical practices to become operational in as little as five days. It facilitates implementation without the requirements for additional personnel or intricate induction procedures, integrates with electronic health records (EHR) for consistent and automated record-keeping, and AI-driven workflows that streamline programme operations while ensuring compliance. Additionally, Medsien provides a full-service delivery model that covers everything from patient identification to tailored ongoing outreach, with care delivery managed by a team of dedicated care partners. Medsien co-founder and CEO Hamed Ahmadi said: "This programme is more than a billing opportunity, it's a transformation in how care is delivered. "We've built APCM to help practices embrace relationship-based, proactive care with confidence and scalability." The launch of Medsien's APCM solution is a step towards lessening the operational burden on healthcare organisations, ensuring compliance with new regulations, and empowering them to excel in the current value-based care landscape. This initiative is part of Medsien's aim to enhance care, leveraging patient-centred design and intelligent systems. "Medsien unveils care management programme" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Forbes
28-05-2025
- Business
- Forbes
InnovationRx: Hinge May Herald A New Wave Of Digital Health IPOs
In this week's edition of InnovationRx, we look at how Hinge Health's successful IPO may be a trendsetter, Indian billionaire Kiran Mazumdar-Shaw's 'biosimilars' business, RFK's changes to Covid vaccine guidance and more. To get it in your inbox, subscribe here. Lex Annison, COO of Hinge Health, Gabriel Mecklenburg, executive chairman, Daniel Perez, CEO, Bianca Buck, head of investor relations, James Budge, CFO, and Jim Pursley, president, ring a ceremonial bell on the floor of the New York Stock Exchange during the company's IPO. © 2025 Bloomberg Finance LP Digital physical therapy company Hinge Health had its initial public offering last week, opening at $37.85. It's currently trading over 10% above that price, giving it a market cap of over $3.2 billion (though this is about half of its peak valuation in 2021). The company's product portfolio offers personalized care plans for patients with chronic conditions, as well as software that coordinates these plans with a patient's doctor. Virtual chronic care company Omada Health also filed to go public earlier this month, and that plus the success of Hinge's IPO may begin a new 'wave of digital health companies seeking a public listing following the COVID-19 pandemic,' Pitchbook analyst Aaron DeGagne wrote in a note last week. He identified several companies, including Spring Health, Zocdoc, Noom and Headspace, that 'will be closely watching Hinge Health's IPO outcome' to decide whether to start the process of going public this year. Kiran Mazumdar Guerin Blask for Forbes Kiran Mazumdar-Shaw's booming drug business started not in a laboratory but in a tin-roofed shed in Bengaluru, the city formerly known as Bangalore and the capital of the southern Indian state of Karnataka. Inside, the 25-year-old was using the knowledge she had learned studying beer brewing in Australia to ferment enzymes for customers like Ocean Spray cranberry juice. Originally she had wanted to be a brewer like her father, but it was 1978 and she couldn't find a job. No one wanted to hire a woman as a brewer. Distraught and disillusioned, Mazumdar-Shaw put her education to another use: making enzymes for industrial uses. In partnership with an Irish entrepreneur who owned a company called Biocon and was looking to expand to India, she set up shop inside that hot shed. 'I call myself an accidental entrepreneur,' she says. Today, Biocon, which is publicly traded in India, brings in $1.9 billion by selling dozens of generic drugs and 'biosimilar' medications. The company also does contract research for other companies through its publicly traded subsidiary Syngene. While Forbes Self-Made Women list includes only women from the United States, Mazumdar-Shaw would easily make the top 20 were she American. She is one of the world's wealthiest self-made female entrepreneurs, with a fortune that Forbes estimates to be $3.2 billion. The biggest part of her empire is a majority-owned private subsidiary called Biocon Biologics, which focuses on biosimilars and represents nearly 55% of the parent company's revenue. Akin to what generics are for chemically synthesized drugs, these cheaper alternatives mimic biologic drugs. As with generics, companies like Mazumdar-Shaw's are allowed to develop biosimilars after a brand-name drug's patents expire. 'These are very complex, expensive drugs, and therefore it's important that companies like ours focus on affordable access,' says Mazumdar-Shaw over tea served by a butler at her Manhattan apartment. Read more here. GSK and Spero Therapeutics announced that their phase 3 clinical trial of tebipenem HBr, an antibiotic geared towards treatment of UTIs, was stopped early after an interim analysis showed significant, positive results in the nearly 1,700 enrolled patients. An independent data monitoring committee recommended the halt, as the study met its primary endpoint of showing the drug was non-inferior to a combination of the antibiotics imipenem and cilastatin. The companies plan to submit the new antibiotic to the FDA for approval in the second half of this year. Plus: Gilgamesh Pharmaceuticals released positive topline results for its phase 2 clinical study of its drug candidate GM-2505 for the treatment of major depressive disorder, finding both rapid and durable decrease in symptoms for patients in the study. AI chatbots. Scribing tools. Insurance claims software. Electronic health records. Abhinav Shashank, cofounder and CEO of digital health startup Innovaccer, looks at all the new technology for healthcare providers and hospital systems and sees a big problem. 'Healthcare is the only place where technology came in and everything became more inefficient,' Shashank told Forbes. The problem is that large healthcare systems, which may have dozens of hospitals and thousands of physicians, have lots of data and a variety of tools to manage it, but no easy way to put them together. Last week, Innovaccer unveiled its solution to that problem: A new software platform called Gravity that's designed to be a one-stop shop for all those disparate tools and vast amounts of data. Read more here. Plus: Ambience Healthcare claims that a new study finds that its AI models reduce medical coding errors by over 25% compared to physicians. HHS Secretary Robert F. Kennedy, Jr. announced that the CDC would be dropping its recommendations for pregnant women and healthy children to receive Covid vaccines. This appears to be at odds with the FDA, which listed pregnancy as a reason for vaccination of people under 65 in its new guidance last week. Paul Offit, a vaccine expert at Children's Hospital of Pennsylvania, told Forbes that 'All this does is put children in harm's way and put pregnant women in harm's way.' RFK Jr. names familiar culprits for the 'sickest generation' in the first MAHA commission report on children's health. Some struggling biotechs are being dragged down by pricey leases, especially in industry hubs like Boston, San Francisco and San Diego. Eli Lilly is buying California-based SiteOne Therapeutics, which is developing a non-opioid pain drug, in a deal worth up to $1 billion. Neuralink, the Elon Musk-founded company developing brain-computer interfaces, has raised $600 million in a venture capital round valuing the company at $9 billion. Measles infections appear to be slowing down in Texas but they're ticking up in other states, including Iowa, which saw its first infection since 2019. Conservative groups are lobbying the Trump Administration for stricter guardrails around in vitro fertilization.
